The EPO published international patent application EP4105232A1 titled 'Immune Cells Overexpressing Cell Signaling Regulatory Factor Introduced from Outside and Use Thereof.' The application covers engineered immune cells with modified cell signaling regulatory factor expression for therapeutic applications, including cancer treatment (A61P 35/00). Inventors include KIM Hoeon, JEON Choonju, WANG Yu, and JUNG Namchul. The filing covers multiple therapeutic protein classifications (C07K 16/28, C07K 14/725, C12N 5/0783) and is designated for all 31 EPO member states.

This is a routine patent publication providing public notice of the application. No compliance actions are required from pharmaceutical or biotechnology companies. Entities developing similar immune cell therapies should review the application claims to assess potential patent landscape implications. Freedom-to-operate analyses may be warranted for companies working in comparable CAR-T or immune cell engineering spaces.